UNSPSC 51281514: Isoniazid calcium pyruvate

This classification denotes an antitubercular agent with the molecular formula 2C9H8N3O3.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M4Q640072Z, chemically known as isonicotinic acid, (1-carboxyethylidene)hydrazide calcium salt (2:1), but more generally known as isoniazid calcium pyruvate, which bears US NIH Compound Identifier 9568684. European Medicines Agency schedules isoniazid calcium pyruvate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08326MIG.

Most nations, for tariff purposes, schedule isoniazid calcium pyruvate under HS 29333999. SMILES: CC(=NNC(=O)C1CCNCC1)C(=O)[O-].CC(=NNC(=O)C1CCNCC1)C(=O)[O-].[CA+2].

UNSPSC 51281514 Isoniazid calcium pyruvate is a Commodity code that in practice sees little state and local procurement activity aligned with its nominal pharmaceutical scope. The recent opportunities tagged under this code do not reflect isoniazid calcium pyruvate procurement; instead, they cover unrelated pharmaceutical products (doxycycline hyclate, ciprofloxacin hydrochloride, naloxone, and drug deactivation systems). The code appears to serve as a catch-all or mislabeled category within state and local procurement systems rather than a dedicated buying line for the specific active pharmaceutical ingredient named in the code title.

State and local procurement activity under this code is sparse and geographically scattered. The Illinois Department of Public Health executed a pharmaceutical warehouse piggyback award through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for doxycycline and ciprofloxacin (IFB 26482DPHPREPDB53392, closed award of $2,999,999.11 over three years), and Seminole County, Florida solicited naloxone and drug deactivation systems in June 2026 (IFB 60459723LAS, response deadline July 26, 2023). The mismatch between the code's pharmaceutical specificity and the actual products being procured suggests that buyers and procurement systems are not consistently applying this Commodity code to its intended use case. Firms pursuing pharmaceutical supply contracts should monitor the broader pharmaceutical family codes rather than rely on this specific code for opportunity visibility.